Although this tumor phenotype (i.e., high AR expression, absence of NE marker expression) still represents the most commonly observed molecular subtype of mCRPC in contemporary rapid autopsy cohorts [49, 53], the emergence of treatment‐induced phenotypes that are characterized by NE marker expression and/or absence of AR expression need to be carefully evaluated [48]. This evidence concerns the gene AR and neoplasm.